Hecht J R
Division of Hematology/Oncology, UCLA School of Medicine, 2345H PVUB, 10945 LeConte Avenue, Los Angeles, CA 90095, USA.
Curr Gastroenterol Rep. 2000 Dec;2(6):478-81. doi: 10.1007/s11894-000-0012-1.
Gastric cancer remains a significant healthcare problem throughout the world and is usually diagnosed at a fairly advanced stage in the West. Despite complete resection of the primary tumor, most patients eventually experience a relapse and die of recurrent disease. Extended surgery has not been shown to improve survival in Western studies. There have been a large number of adjuvant chemotherapy trials over the past several decades, most with negative results. More recently, there is hope for improving these dismal results with a meta-analysis showing a benefit for adjuvant chemotherapy and a large randomized trial, INT-0116, which has just reported a significant survival advantage with combined chemoradiation. These results make adjuvant therapy for completely resected gastric carcinoma the new standard of care, except in the uncommon setting of early intramucosal cancers.
胃癌在全球范围内仍然是一个重大的医疗保健问题，在西方通常在相当晚期才被诊断出来。尽管对原发性肿瘤进行了完全切除，但大多数患者最终还是会复发并死于复发性疾病。在西方研究中，扩大手术并未显示能提高生存率。在过去几十年里有大量辅助化疗试验，大多数结果为阴性。最近，有希望改善这些糟糕结果，一项荟萃分析显示辅助化疗有益，还有一项大型随机试验INT - 0116刚刚报告了联合放化疗具有显著的生存优势。这些结果使完全切除的胃癌辅助治疗成为新的标准治疗方法，但早期黏膜内癌这种不常见情况除外。
